Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
Metrics to compare | ZOE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZOEPeersSector | |
---|---|---|---|---|
P/E Ratio | 29.2x | 10.1x | −0.5x | |
PEG Ratio | 3.73 | −0.13 | 0.00 | |
Price/Book | 15.2x | 1.5x | 2.6x | |
Price / LTM Sales | 7.9x | 1.0x | 3.0x | |
Upside (Analyst Target) | - | 25.4% | 54.1% | |
Fair Value Upside | Unlock | 15.3% | 9.4% | Unlock |